
Recent failures in Phase 3 trials for high-risk #MDS necessitate a shift in drug development. Future strategies must prioritize novel combinations and distinct molecular targeting beyond hypomethylating agents.
Read the review: bit.ly/4uQnRoi
#HemOnc #ClinicalTrials
English
